Antoine G van der Heijden Selected Research

Hyperthermia

1/2016	Effects of hyperthermia in neutralising mechanisms of drug resistance in non-muscle-invasive bladder cancer.
10/2015	Urinary cytokines in patients treated with intravesical mitomycin-C with and without hyperthermia.
6/2007	The influence of thermo-chemotherapy on bladder tumours: an immunohistochemical analysis.
4/2005	Effect of hyperthermia on the cytotoxicity of 4 chemotherapeutic agents currently used for the treatment of transitional cell carcinoma of the bladder: an in vitro study.
11/2004	The effect of hyperthermia on mitomycin-C induced cytotoxicity in four human bladder cancer cell lines.
9/2003	Future strategies in the diagnosis, staging and treatment of bladder cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Antoine G van der Heijden Research Topics

Disease

25	Urinary Bladder Neoplasms (Bladder Cancer) 01/2024 - 09/2003
13	Neoplasms (Cancer) 09/2023 - 04/2005
12	Non-Muscle Invasive Bladder Neoplasms 04/2024 - 06/2009
8	Carcinoma (Carcinomatosis) 02/2024 - 04/2006
6	Hyperthermia 01/2016 - 09/2003
1	Hypoxia (Hypoxemia) 01/2023
1	Respiratory Tract Infections (Respiratory Tract Infection) 01/2023
1	Lymphatic Metastasis 04/2022
1	Neoplasm Metastasis (Metastasis) 01/2022
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2020
1	Carcinoma in Situ 01/2019
1	Transitional Cell Carcinoma 11/2004
1	Body Weight (Weight, Body) 02/2004

Drug/Important Bio-Agent (IBA)

10	Mitomycin (Mitomycin-C)FDA LinkGeneric 02/2024 - 09/2003
3	Gemcitabine FDA Link 04/2024 - 09/2003
3	Biomarkers (Surrogate Marker)IBA 01/2023 - 01/2018
3	apaziquone (E 09)IBA 06/2009 - 04/2005
2	Immune Checkpoint InhibitorsIBA 01/2024 - 09/2023
2	DNA (Deoxyribonucleic Acid)IBA 09/2023 - 01/2021
2	NivolumabIBA 07/2023 - 01/2023
2	IpilimumabIBA 07/2023 - 01/2023
2	Cisplatin (Platino)FDA LinkGeneric 01/2023 - 01/2022
2	Epirubicin (Ellence)FDA LinkGeneric 09/2014 - 04/2005
1	avelumabIBA 01/2024
1	pembrolizumabIBA 01/2024
1	Circulating Tumor DNAIBA 09/2023
1	Carboplatin (JM8)FDA LinkGeneric 01/2022
1	PlatinumIBA 01/2021
1	Biocompatible Materials (Biomaterials)IBA 01/2021
1	CytokinesIBA 10/2015
1	Toll-Like Receptor 7IBA 06/2015
1	Imiquimod (Aldara)FDA LinkGeneric 06/2015
1	Tumor Biomarkers (Tumor Markers)IBA 10/2006
1	Pemetrexed (MTA)FDA Link 04/2006
1	5-aminolevulinic acid hexyl ester FDA Link 03/2005
1	Chlorthalidone (Chlortalidone)FDA LinkGeneric 02/2004
1	Amiloride (Midamor)FDA LinkGeneric 02/2004
1	Colloids (Colloid)IBA 02/2004
1	pirarubicinIBA 09/2003
1	valrubicin (AD 32)FDA Link 09/2003

Therapy/Procedure

16	Cystectomy 01/2023 - 09/2003
11	Therapeutics 04/2024 - 09/2003
8	Drug Therapy (Chemotherapy) 01/2023 - 04/2005
6	Immunotherapy 01/2024 - 01/2016
5	Intravesical Administration 02/2024 - 10/2006
3	Transurethral Resection of Bladder 01/2021 - 06/2009
2	Lymph Node Excision (Lymph Node Dissection) 04/2022 - 12/2014
2	Radiotherapy 01/2020 - 09/2003
1	Aftercare (After-Treatment) 11/2023
1	Preoperative Exercise 01/2023
1	Neoadjuvant Therapy 01/2023
1	Length of Stay 01/2023
1	Urinary Diversion (Ileal Conduit) 11/2021
1	Induced Hyperthermia (Thermotherapy) 01/2021
1	Nephroureterectomy 01/2021
1	Complementary Therapies (Alternative Medicine) 01/2019
1	Photochemotherapy (Photodynamic Therapy) 09/2003